Expanding the Role of Suprachoroidal Injections
Clinical data support this targeted route for small molecules, gene therapy, and oncologic agents, with a good safety profile and potential to reduce treatment burden.
Clinical Scorecard: Expanding the Role of Suprachoroidal Injections
At a Glance
Category Detail
Condition Uveitic macular edema and other macular disorders Key Mechanisms Targeted drug delivery via the suprachoroidal space (SCS) minimizes exposure to anterior-segment structures. Target Population Patients with macular disorders, particularly those unresponsive to standard treatments. Care Setting Outpatient settings under local anesthesia.
Key Highlights
First FDA-approved therapy for suprachoroidal use: Xipere (triamcinolone acetonide). Suprachoroidal injections provide targeted delivery with reduced systemic side effects. Innovative delivery systems include catheter-based and microneedle-based technologies. Durability of drugs in SCS influenced by particle size and relative insolubility. Emerging technologies like the Everads Injector show promise in clinical trials. Guideline-Based Recommendations
Diagnosis
Assess for uveitic macular edema and other macular disorders. Management
Consider suprachoroidal injections for patients unresponsive to traditional therapies. Monitoring & Follow-up
Monitor for therapeutic efficacy and adverse effects post-injection. Risks
Potential for unintended effects on anterior-segment structures. Patient & Prescribing Data
Patients with diabetic macular edema and other macular disorders.
Suprachoroidal delivery allows for sustained drug release and targeted action.
Clinical Best Practices
Utilize catheter-based systems for precise delivery to the SCS. Employ real-time imaging for confirmation of injection accuracy. Consider patient convenience and comfort during outpatient procedures. References
